Last updated: June 5, 2026
LOTENSIN HCT Suppliers (Benazepril + Hydrochlorothiazide): Who Manufactures and Supplies the Product and Active Ingredients
Executive summary: LOTENSIN HCT (benazepril hydrochloride + hydrochlorothiazide) is a branded fixed-dose combination supplied through the drug’s label network and the underlying API and intermediate supply chain. The practical supplier set for business planning is: (1) the marketing authorization holder and label-manufacturer(s) for finished drug product (FDF), (2) the API manufacturers for benazepril HCl and hydrochlorothiazide, and (3) contract packagers and logistics vendors tied to FDA labeling and distribution. No usable supplier identities can be stated from the information provided.
Which companies supply LOTENSIN HCT (benazepril hydrochloride hydrochlorothiazide) finished drug product?
Featured snippet: Finished drug product supplier identities for LOTENSIN HCT are not provided in the input, and cannot be derived without the product’s label/manufacturer listings (e.g., FDA label section, DailyMed, Orange Book, or the NDA holder’s manufacturing site list).
What to check on the LOTENSIN HCT label for manufacturer-of-record
- Applicant/holder listed on the FDA label or DailyMed.
- “Manufactured for” or “Distributed by” company fields.
- Label section that lists the manufacturer address for the dosage form.
- National Drug Code (NDC) linked to specific packaging and site.
Why NDC-specific suppliers matter
Same branded drug strength can have multiple NDCs tied to different manufacturing sites and packaging vendors. Supplier due diligence for procurement or licensing depends on the NDC block and dosage form (tablet strength) rather than the brand name alone.
What suppliers make the benazepril hydrochloride and hydrochlorothiazide APIs used in LOTENSIN HCT?
Featured snippet: API suppliers for benazepril hydrochloride and hydrochlorothiazide are not provided in the input, and cannot be listed without API listing sources (e.g., Orange Book ANDA disclosures, DMFs, or published supplier registries).
Benazepril HCl supply chain checkpoints
- DMF holder names for benazepril hydrochloride.
- Contract manufacturer sites used for API batch production.
- Common impurity specs and polymorph control requirements tied to the brand’s clinical grade.
Hydrochlorothiazide supply chain checkpoints
- API producer sites for hydrochlorothiazide with controlled particle size/grade.
- Presence of multiple crystal forms and how the supplier qualifies them for solid oral formulations.
How does the LOTENSIN HCT Orange Book listing determine supplier and patent-to-manufacturing linkage?
Featured snippet: Orange Book listings can link to NDA/ANDA product details and sometimes to specific manufacturers, but the input does not include the Orange Book entry, NDA number, or listed labeler/manufacturer.
What Orange Book data points typically help supplier mapping
- NDA holder (application holder).
- Dosage forms and strengths.
- Listed patents and exclusivity (useful for licensing and risk, less direct for procurement).
- Sometimes labeler/manufacturer identifiers tied to product presentation.
What are the most common contract manufacturing and packaging vendors used for benazepril HCT tablets?
Featured snippet: Contract manufacturing and packaging vendor identities are not provided in the input and cannot be stated without label-manufacturer verification for LOTENSIN HCT’s NDCs.
Why vendor naming must be NDC-anchored
Contract manufacturing firms may not be consistent across strengths. Packaging operations can shift between 30-day bottles, 90-day bottles, and unit dose channels.
Which generic or authorized-duplicate manufacturers supply the same combination products that compete with LOTENSIN HCT?
Featured snippet: Competitor supplier identities depend on which specific generic(s) are marketed against the same NDC strength, and those data are not provided.
Procurement and licensing angle
For supplier benchmarking, the most actionable view is to map:
- ANDA number to labeler,
- NDC to manufacturing site,
- ANDA approval date and revisions,
- current GMP inspection status at the manufacturing sites.
What procurement risks exist if a substitute supplier for LOTENSIN HCT is used?
Featured snippet: Risk assessment depends on whether the substitute is the same NDC presentation and whether the API and tablet formulation are equivalent at the established criteria. The input does not provide supplier, NDC, or product equivalence facts.
Core risk dimensions
- API source changes impacting impurity profile and dissolution.
- Tablet manufacturing site changes affecting blend uniformity and compression parameters.
- Distribution channel constraints tied to temperature or humidity controls.
How strong is the supplier base for benazepril HCT: API availability vs. finished product bottlenecks?
Featured snippet: A supplier-base strength analysis requires the API and FDF manufacturer lists, lead times, and inspection history. None of those are present in the input.
Data required to quantify supplier concentration
- API producer count meeting the brand’s specifications.
- DMF holder overlap across multiple finished-product applicants.
- Historic FDA facility inspection outcomes for the manufacturing sites.
Key Takeaways
- Supplier names for LOTENSIN HCT cannot be provided from the information given.
- Supplier identification for business use must be anchored to (1) LOTENSIN HCT NDA label/manufacturer-of-record for each NDC, and (2) benazepril HCl and hydrochlorothiazide API supplier sources tied to the approved manufacturing network.
- The actionable next step in supplier due diligence is NDC- and label-section-based verification, then mapping API and intermediate sources through the approved supply chain.
FAQs
- How do I identify the manufacturer-of-record for LOTENSIN HCT for a specific NDC?
- Which sources list the benazepril hydrochloride API manufacturing sites used in branded combination tablets?
- Do different LOTENSIN HCT tablet strengths use different FDF manufacturing facilities?
- What documentation supports supplier qualification for benazepril HCT tablets in regulated procurement?
- How does a change in API supplier affect impurity and dissolution specifications for fixed-dose combinations?
References
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database).
- DailyMed. LOTENSIN HCT (benazepril hydrochloride and hydrochlorothiazide) prescribing information and label details. (Database).
